This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by D'Amico, A. V. Articles by Catalona, W. J. Search for Related Content PubMed PubMed Citation Articles by D'Amico, A. V. Articles by Catalona, W. J. Social Bookmarking                            What's this?

Identifying Patients at Risk for Significant Versus Clinically Insignificant Postoperative Prostate-Specific Antigen Failure

From the Department of Radiation Oncology, Brigham and Women's Hospital and Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA; Department of Statistics, University of Connecticut, Storrs, CT; Department of Psychiatry, Washington University School of Medicine, St Louis, MO; and Department of Urology, Northwestern Feinberg School of Medicine, Chicago, IL

Address reprint requests to Anthony V. D'Amico, MD, PhD, Brigham and Women's Hospital, 75 Francis St, Department of Radiation Oncology L-2 Level, Boston, MA 02115; e-mail: adamico{at}lroc.harvard.edu

PURPOSE: We evaluated whether men at risk for significant versus clinically insignificant prostate-specific antigen (PSA) failure after radical prostatectomy could be identified using information available at diagnosis.

PATIENTS AND METHODS: A prospective prostate cancer screening study that enrolled, diagnosed, and treated 1,011 men with radical prostatectomy at Barnes-Jewish Hospital (St Louis, MO) from January 1, 1989, to June 1, 2002, for localized prostate cancer formed the study cohort. Preoperative predictors of a postoperative PSA doubling time (DT) of less than 3 months and more than 12 months or no PSA failure were identified using logistic regression.

RESULTS: A preoperative PSA velocity more than 2.0 ng/mL/yr (P = .001) and biopsy Gleason score 7 (P = .006) or 8 to 10 (P = .003) were significantly associated with having a postoperative PSA DT less than 3 months. A PSA level less than 10 ng/mL (P = .005), a nonpalpable cancer (P = .001) with a Gleason score 6 (P = .0002), and a preoperative PSA increase that did not exceed 0.5 ng/mL/yr (P = .03) were significantly associated with a postoperative PSA DT of at least 12 months or no PSA failure. Most men with these preoperative characteristics and a postoperative PSA DT of 12 months or more had a persistent postoperative PSA level of at least 0.2 ng/mL that did not exceed 0.25 ng/mL after a median follow-up of 3.6 years.

CONCLUSION: A postoperative PSA DT less than 3 months is associated with a preoperative PSA velocity more than 2.0 ng/mL/yr and high-grade disease. Select men with a postoperative PSA DT more than 12 months may not require salvage radiation therapy.

Authors' disclosures of potential conflicts of interest are found at the end of this article.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				O. W. Brawley, D. P. Ankerst, and I. M. Thompson Screening for Prostate Cancer CA Cancer J Clin, July 1, 2009; 59(4): 264 - 273. [Abstract] [Full Text] [PDF]

				W. D. Stein, J. Yang, S. E. Bates, and T. Fojo Bevacizumab Reduces the Growth Rate Constants of Renal Carcinomas: A Novel Algorithm Suggests Early Discontinuation of Bevacizumab Resulted in a Lack of Survival Advantage Oncologist, October 1, 2008; 13(10): 1055 - 1062. [Abstract] [Full Text] [PDF]

				W. D. Stein, W. D. Figg, W. Dahut, A. D. Stein, M. B. Hoshen, D. Price, S. E. Bates, and T. Fojo Tumor Growth Rates Derived from Data for Patients in a Clinical Trial Correlate Strongly with Patient Survival: A Novel Strategy for Evaluation of Clinical Trial Data Oncologist, October 1, 2008; 13(10): 1046 - 1054. [Abstract] [Full Text] [PDF]

				S. Tomioka, M. Shimbo, Y. Amiya, H. Nakatsu, S. Murakami, and J. Shimazaki Outcome of Patients with Hormone-Refractory Prostate Cancer: Prognostic Significance of Prostate-Specific Antigen-Doubling Time and Nadir Prostate-Specific Antigen Jpn. J. Clin. Oncol., January 1, 2008; 38(1): 36 - 42. [Abstract] [Full Text] [PDF]

				R. W. Veltri, M. C. Miller, S. Isharwal, C. Marlow, D. V. Makarov, and A. W. Partin Prediction of Prostate-Specific Antigen Recurrence in Men with Long-term Follow-up Postprostatectomy Using Quantitative Nuclear Morphometry Cancer Epidemiol. Biomarkers Prev., January 1, 2008; 17(1): 102 - 110. [Abstract] [Full Text] [PDF]

				S. S. Chang and M. B. Amin Utilizing the Tumor-Node-Metastasis Staging for Prostate Cancer: The Sixth Edition, 2002 CA Cancer J Clin, January 1, 2008; 58(1): 54 - 59. [Abstract] [Full Text] [PDF]

				F. Shimizu, A. Igarashi, T. Fukuda, Y. Kawachi, S. Minowada, Y. Ohashi, and M. Fujime Decision Analyses in Consideration of Treatment Strategies for Patients with Biochemical Failure After Curative Therapy on Clinically Localized Prostate Cancer in the Prostate-Specific Antigen Era Jpn. J. Clin. Oncol., October 22, 2007; (2007) hym105v1. [Abstract] [Full Text] [PDF]

				F. Shimizu, S. Tanaka, Y. Matsuyama, T. Tominaga, Y. Ohashi, and M. Fujime Efficiency of Ultrasensitive Prostate-specific Antigen Assay in Diagnosing Biochemical Failure After Radical Prostatectomy Jpn. J. Clin. Oncol., June 1, 2007; 37(6): 446 - 451. [Abstract] [Full Text] [PDF]

				A. V. D'Amico, M. Loffredo, A. A. Renshaw, B. Loffredo, and M.-H. Chen Six-Month Androgen Suppression Plus Radiation Therapy Compared With Radiation Therapy Alone for Men With Prostate Cancer and a Rapidly Increasing Pretreatment Prostate-Specific Antigen Level J. Clin. Oncol., September 1, 2006; 24(25): 4190 - 4195. [Abstract] [Full Text] [PDF]